1
|
Echeverri D, Calucho E, Marrugo-Ramírez J, Álvarez-Diduk R, Orozco J, Merkoçi A. Capacitive immunosensing at gold nanoparticle-decorated reduced graphene oxide electrodes fabricated by one-step laser nanostructuration. Biosens Bioelectron 2024; 252:116142. [PMID: 38401281 DOI: 10.1016/j.bios.2024.116142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 02/01/2024] [Accepted: 02/18/2024] [Indexed: 02/26/2024]
Abstract
Nanostructured electrochemical biosensors have ushered in a new era of diagnostic precision, offering enhanced sensitivity and specificity for clinical biomarker detection. Among them, capacitive biosensing enables ultrasensitive label-free detection of multiple molecular targets. However, the complexity and cost associated with conventional fabrication methods of nanostructured platforms hinder the widespread adoption of these devices. This study introduces a capacitive biosensor that leverages laser-engraved reduced graphene oxide (rGO) electrodes decorated with gold nanoparticles (AuNPs). The fabrication involves laser-scribed GO-Au3+ films, yielding rGO-AuNP electrodes, seamlessly transferred onto a PET substrate via a press-stamping methodology. These electrodes have a remarkable affinity for biomolecular recognition after being functionalized with specific bioreceptors. For example, initial studies with human IgG antibodies confirm the detection capabilities of the biosensor using electrochemical capacitance spectroscopy. Furthermore, the biosensor can quantify CA-19-9 glycoprotein, a clinical cancer biomarker. The biosensor exhibits a dynamic range from 0 to 300 U mL-1, with a limit of detection of 8.9 U mL-1. Rigorous testing with known concentrations of a pretreated CA-19-9 antigen from human fluids confirmed their accuracy and reliability in detecting the glycoprotein. This study signifies notable progress in capacitive biosensing for clinical biomarkers, potentially leading to more accessible and cost-effective point-of-care solutions.
Collapse
Affiliation(s)
- Danilo Echeverri
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and the Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain; Max Planck Tandem Group in Nanobioengineering, Institute of Chemistry, Faculty of Natural and Exact Sciences, University of Antioquia, Complejo Ruta N, Calle 67 N° 52-20, 050010, Medellín, Colombia
| | - Enric Calucho
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and the Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Bellaterra, 08193, Barcelona, Spain
| | - Jose Marrugo-Ramírez
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and the Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Bellaterra, 08193, Barcelona, Spain
| | - Ruslán Álvarez-Diduk
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and the Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain.
| | - Jahir Orozco
- Max Planck Tandem Group in Nanobioengineering, Institute of Chemistry, Faculty of Natural and Exact Sciences, University of Antioquia, Complejo Ruta N, Calle 67 N° 52-20, 050010, Medellín, Colombia.
| | - Arben Merkoçi
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), CSIC and the Barcelona Institute of Science and Technology (BIST), Campus UAB, Bellaterra, 08193, Barcelona, Spain; ICREA Institució Catalana de Recerca i Estudis Avançats, Passeig de Lluís Companys, 23, 08010, Barcelona, Spain.
| |
Collapse
|
2
|
Hu L, Calucho E, Fuentes-Chust C, Parolo C, Idili A, Álvarez-Diduk R, Rivas L, Merkoçi A. Selection and characterisation of bioreceptors to develop nanoparticle-based lateral-flow immunoassays in the context of the SARS-CoV-2 outbreak. Lab Chip 2022; 22:2938-2943. [PMID: 35903978 DOI: 10.1039/d2lc00486k] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
This manuscript aims at raising the attention of the scientific community to the need for better characterised bioreceptors for fast development of point-of-care diagnostic devices able to support mass frequency testing. Particularly, we present the difficulties encountered in finding suitable antibodies for the development of a lateral flow assay for detecting the nucleoprotein of SARS-CoV-2.
Collapse
Affiliation(s)
- Liming Hu
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Enric Calucho
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Celia Fuentes-Chust
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Claudio Parolo
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
- ISGlobal, Barcelona Centre for International Health Research (CRESIB), Hospital Clínic (Department of International Health), Universitat de Barcelona, Barcelona, Spain
| | - Andrea Idili
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Ruslan Álvarez-Diduk
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Lourdes Rivas
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
| | - Arben Merkoçi
- Nanobioelectronics & Biosensors Group, Catalan Institute of Nanoscience and Nanotechnology (ICN2), CSIC, BIST, Campus UAB, 08193, Bellaterra, Barcelona, Spain.
- ICREA, Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
| |
Collapse
|
3
|
Usha SP, Manoharan H, Deshmukh R, Álvarez-Diduk R, Calucho E, Sai VVR, Merkoçi A. Attomolar analyte sensing techniques (AttoSens): a review on a decade of progress on chemical and biosensing nanoplatforms. Chem Soc Rev 2021; 50:13012-13089. [PMID: 34673860 DOI: 10.1039/d1cs00137j] [Citation(s) in RCA: 14] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
Detecting the ultra-low abundance of analytes in real-life samples, such as biological fluids, water, soil, and food, requires the design and development of high-performance biosensing modalities. The breakthrough efforts from the scientific community have led to the realization of sensing technologies that measure the analyte's ultra-trace level, with relevant sensitivity, selectivity, response time, and sampling efficiency, referred to as Attomolar Analyte Sensing Techniques (AttoSens) in this review. In an AttoSens platform, 1 aM detection corresponds to the quantification of 60 target analyte molecules in 100 μL of sample volume. Herein, we review the approaches listed for various sensor probe design, and their sensing strategies that paved the way for the detection of attomolar (aM: 10-18 M) concentration of analytes. A summary of the technological advances made by the diverse AttoSens trends from the past decade is presented.
Collapse
Affiliation(s)
- Sruthi Prasood Usha
- Biomedical Engineering, Department of Applied Mechanics, Indian Institute of Technology Madras (IITM), India.
| | - Hariharan Manoharan
- Biomedical Engineering, Department of Applied Mechanics, Indian Institute of Technology Madras (IITM), India.
| | - Rehan Deshmukh
- Biomedical Engineering, Department of Applied Mechanics, Indian Institute of Technology Madras (IITM), India.
| | - Ruslan Álvarez-Diduk
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), Campus UAB, Barcelona, Spain.
| | - Enric Calucho
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), Campus UAB, Barcelona, Spain.
| | - V V R Sai
- Biomedical Engineering, Department of Applied Mechanics, Indian Institute of Technology Madras (IITM), India.
| | - Arben Merkoçi
- Nanobioelectronics & Biosensors Group, Institut Català de Nanociència i Nanotecnologia (ICN2), Campus UAB, Barcelona, Spain. .,ICREA, Institució Catalana de Recercai Estudis Avançats, Barcelona, Spain
| |
Collapse
|
4
|
Rosati G, Idili A, Parolo C, Fuentes-Chust C, Calucho E, Hu L, Castro e Silva CDC, Rivas L, Nguyen EP, Bergua JF, Alvárez-Diduk R, Muñoz J, Junot C, Penon O, Monferrer D, Delamarche E, Merkoçi A. Nanodiagnostics to Face SARS-CoV-2 and Future Pandemics: From an Idea to the Market and Beyond. ACS Nano 2021; 15:17137-17149. [PMID: 34705433 PMCID: PMC8565461 DOI: 10.1021/acsnano.1c06839] [Citation(s) in RCA: 18] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Accepted: 10/20/2021] [Indexed: 05/24/2023]
Abstract
The COVID-19 pandemic made clear how our society requires quickly available tools to address emerging healthcare issues. Diagnostic assays and devices are used every day to screen for COVID-19 positive patients, with the aim to decide the appropriate treatment and containment measures. In this context, we would have expected to see the use of the most recent diagnostic technologies worldwide, including the advanced ones such as nano-biosensors capable to provide faster, more sensitive, cheaper, and high-throughput results than the standard polymerase chain reaction and lateral flow assays. Here we discuss why that has not been the case and why all the exciting diagnostic strategies published on a daily basis in peer-reviewed journals are not yet successful in reaching the market and being implemented in the clinical practice.
Collapse
Affiliation(s)
- Giulio Rosati
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Andrea Idili
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Claudio Parolo
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Celia Fuentes-Chust
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Enric Calucho
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Liming Hu
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Cecilia de Carvalho Castro e Silva
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
- MackGraphe-Mackenzie
Institute for Research in Graphene and Nanotechnologies, Mackenzie Presbyterian University, Consolação street 930, 01302-907 São Paulo, Brazil
| | - Lourdes Rivas
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Emily P. Nguyen
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - José F. Bergua
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - Ruslan Alvárez-Diduk
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| | - José Muñoz
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
- ISGlobal-Barcelona
Institute for Global Health, Carrer del Rosselló, 132, 08036 Barcelona, Spain
| | - Christophe Junot
- Université
Paris-Saclay, CEA, INRAE Departement Médicaments
et Technologies pour la Santé SPI, 91191 Gif-sur-Yvette cedex, France
| | - Oriol Penon
- Asphalion, Carrer de Tarragona 151-157, 08014 Barcelona, Spain
| | | | | | - Arben Merkoçi
- Institut
Català de Nanociència i Nanotecnologia, Edifici ICN2 Campus UAB, 08193 Bellaterra, Barcelona, Spain
| |
Collapse
|